# Peter Fedichev

> Peter Fedichev is a theoretical physicist turned longevity entrepreneur who co-founded Gero, a biotech AI company applying physics-based generative AI models to crack the root causes of aging. A former top-2 cited Russian physicist under 35, he traded quantum gases for aging clocks, building a platform that predicted biological age from wearable data before it was fashionable, secured a Pfizer collaboration, and landed a potential $250M deal with Chugai Pharmaceutical (Roche Group) in 2025 - all while publishing over 75 scientific papers and winning a $10,000 prize for winning a public debate on defeating aging.

- **Role:** Co-founder & CEO at Gero
- **Organizations:** Gero, Moscow Institute of Physics and Technology, Quantum Pharmaceuticals
- **Nationality:** Russian
- **Education:** M.Sc. in Theoretical Physics, Moscow Institute of Physics and Technology (MIPT), Ph.D. cum laude in Theoretical Physics, University of Amsterdam (AMOLF Institute)
- **Known for:** Top-2 cited Russian physicist under age 35 before pivoting to biotech, Co-founded Gero, securing collaborations with Pfizer (2023) and Chugai Pharmaceutical with up to $250M in milestone payments (2025), Developed GeroSense - AI biological age prediction from smartphone/wearable data (2018), outperforming all prior models

## Career timeline

- **1990s** — Researcher at Kurchatov Institute, Moscow; then FOM Institute for Molecular and Atomic Physics, Amsterdam
- **Early 2000s** — Assistant Professor, Institute for Theoretical Physics, University of Innsbruck (Austria) - condensed matter and quantum-gas systems
- **2000s** — Co-founded Quantum Pharmaceuticals - computational drug design using quantum mechanics for protein-ligand binding affinity predictions
- **2015** — Published first paper on aging mechanisms; pivoted research focus entirely to longevity science
- **2018** — Co-founded Gero in Singapore with Maxim Kholin; launched GeroSense AI biological age prediction from wearable data
- **2021** — Nature Communications study on human resilience decline and maximum lifespan limits published
- **2023** — Research collaboration with Pfizer on therapeutic targets for fibrotic diseases; raised $6M Series A extension
- **2024** — Won 'How to Defeat Aging' debate at Foresight Institute ($10K prize); named co-editor of Nature's Gerophysics collection; Tokyo Longevity Summit speaker
- **2025** — Joint research and license agreement with Chugai Pharmaceutical (Roche Group) - potential $250M milestone and royalties; launched ProtoBind-Diff AI model for structure-free drug design

## Achievements

- Top-2 cited Russian physicist under age 35 before pivoting to biotech
- Co-founded Gero, securing collaborations with Pfizer (2023) and Chugai Pharmaceutical with up to $250M in milestone payments (2025)
- Developed GeroSense - AI biological age prediction from smartphone/wearable data (2018), outperforming all prior models
- Published 75+ scientific papers with 7,500+ citations (Google Scholar)
- Named 'Rising Star of Longevity' by Business Insider
- Co-editor of Nature's 2024 Gerophysics collection (with Brian K. Kennedy)
- Won 'How to Defeat Aging' debate at Foresight Institute (May 2024), awarded $10,000
- Raised $8.2M total funding for Gero to advance physics-based AI drug discovery
- Head of Biological Systems Simulation Lab at MIPT
- Launched ProtoBind-Diff (2025) - first AI model for structure-free drug design using only protein sequence

## Latest updates

- **2026-04** — Presented 'How We Should Target Aging' discussing his three-variable aging model (stress, noise, damage)
- **2025-08** — Published 'A Minimal Model Explains Aging Regimes and Guides Intervention Strategies' with J. Gruber
- **2025-07** — Gero signed joint research and license agreement with Chugai Pharmaceutical (Roche Group) for novel therapies for age-related diseases - potential $250M in milestones and royalties
- **2025-03** — Presented 'Beyond Hallmarks: A Thermodynamic Framework for Radical Lifespan Extension' at Global Conference on Gerophysics
- **2025-01** — Gero launched ProtoBind-Diff - first AI model for structure-free drug design using only protein sequence
- **2024-07** — Featured speaker at Tokyo Longevity Summit
- **2024-05** — Won 'How to Defeat Aging' debate at Foresight Institute, awarded $10,000 prize; expert jury voted 42-38 in his favor
- **2024-01** — Named co-editor of Nature's Gerophysics collection alongside Brian K. Kennedy
- **2023-10** — Gero raised $6M Series A extension led by Melnichek Investments, with VitaDAO and EPAM co-founder participating
- **2023-01** — Announced research collaboration with Pfizer to identify therapeutic targets for fibrotic diseases

## Links

- Website: https://gero.ai
- LinkedIn: https://www.linkedin.com/in/peterfedichev/
- Twitter/X: https://twitter.com/fedichev
- YouTube: https://www.youtube.com/@fedichev
- Facebook: https://www.facebook.com/geroscience

---

Profile page: https://yespress.io/peter-fedichev
Published by YesPress — https://yespress.io
Last updated: 2026-05-24